ICU Medical Inc

Price has decisively broken key support and entered a structured downtrend, with EMAs rolling over and lower highs confirmed. Oversold conditions and extension below the EMA stack suggest caution against immediate selling. Medium-term bias is bearish, so execution should be deferred and focused on pullbacks into the broken support zone near prior resistance.

• ↑Adjusted EPS $2.37 (+13% YoY) beat estimates; FY26 EPS guidance raised to $8.60–$9.00.
• ↑Q2 revenue $548M (+1% YoY, +6% organic), adjusted EBITDA $110M (20% margin, +10% YoY).
• ↓Negative profitability factor indicates ongoing margin pressures and pricing headwinds.